Julia Marie Eastland - Jan 24, 2023 Form 4 Insider Report for Harpoon Therapeutics, Inc. (HARP)

Role: President and CEO, Director
Signature: /s/ Frank Lanza, Attorney-in-Fact
Stock symbol: HARP
Transactions as of: Jan 24, 2023
Transactions value $: $0
Form type: 4
Date filed: 1/26/2023, 03:05 PM
Previous filing: Jun 3, 2022
Next filing: Mar 27, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HARP	Employee Stock Option (right to buy)	Award	$0	+408K		$0.00	408K	Jan 24, 2023	Common Stock	408K	$0.89	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/48th of 203,800 stock option, representing one-half of the total option grant, will vest and become exercisable monthly on the same day of each month following the vesting commencement date of January 24, 2023 (the "VCD"), and 25% of 203,800 stock option, representing the second one-half of the total option grant, will vest and become exercisable every six months following the VCD, all subject to the continuing employment of the Reporting Person on each vesting date.

Content

1/48th of 203,800 stock option, representing one-half of the total option grant, will vest and become exercisable monthly on the same day of each month following the vesting commencement date of January 24, 2023 (the "VCD"), and 25% of 203,800 stock option, representing the second one-half of the total option grant, will vest and become exercisable every six months following the VCD, all subject to the continuing employment of the Reporting Person on each vesting date.